ciglitazone has been researched along with Thyroid Neoplasms in 4 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to examine the effects of two PPARgamma agonists, ciglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 (15dPGJ2), on the survival of thyroid carcinoma CGTH W-2 cells." | 3.73 | Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. ( Chen, Y; Huang, SH; Wang, SM; Wu, JC, 2006) |
| "Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy." | 2.43 | Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment. ( Angelos, P; Sturgeon, C, 2006) |
| "Anaplastic thyroid cancer (ATC) is an extremely aggressive tumor characterized by marked epithelial mesenchymal transition, which leads, almost invariably, to death." | 1.33 | Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. ( Aiello, A; Belfiore, A; Conte, E; Frasca, F; Genua, M; Murabito, A; Pandini, G; Sacco, A; Vigneri, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martelli, ML | 1 |
| Iuliano, R | 1 |
| Le Pera, I | 1 |
| Sama', I | 1 |
| Monaco, C | 1 |
| Cammarota, S | 1 |
| Kroll, T | 1 |
| Chiariotti, L | 1 |
| Santoro, M | 1 |
| Fusco, A | 1 |
| Sturgeon, C | 1 |
| Angelos, P | 1 |
| Aiello, A | 1 |
| Pandini, G | 1 |
| Frasca, F | 1 |
| Conte, E | 1 |
| Murabito, A | 1 |
| Sacco, A | 1 |
| Genua, M | 1 |
| Vigneri, R | 1 |
| Belfiore, A | 1 |
| Chen, Y | 1 |
| Wang, SM | 1 |
| Wu, JC | 1 |
| Huang, SH | 1 |
1 review available for ciglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Cisplat | 2006 |
3 other studies available for ciglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth.
Topics: Apoptosis; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Depende | 2002 |
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Caspase 3; Caspase 7; Caspases; Cell Cyc | 2006 |
Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line.
Topics: Apoptosis; Asian People; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Dru | 2006 |